Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://www.ncbi.nlm.nih.gov/pubmed/31640191
http://dx.doi.org/10.3390/medicina55100707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://www.ncbi.nlm.nih.gov/pubmed/31640191
http://dx.doi.org/10.3390/medicina55100707

Ejemplares similares